Tag: Ocugen

Friday's trading activity for Ocugen presented a market conundrum. While the share price itself declined, a surge in bullish options ...

In a decisive move aligning leadership incentives with corporate goals, Ocugen, Inc. has established a substantial performance-based equity award for ...

Shares of clinical-stage biopharmaceutical company Ocugen saw elevated trading activity on Monday, with volume running 72% above the average. This ...

Ocugen's stock closed at $1.38 on Friday, marking a single-day gain of 5.34%. This advance represents the third consecutive trading ...

The biotechnology firm Ocugen enters the new trading week with positive momentum. Following a multi-day advance, investors are assessing whether ...

Investors in Ocugen, a biotechnology firm focused on genetic treatments for rare eye diseases, were met with unsettling news in ...

Investors in Ocugen are facing a critical test of resolve. The biotech firm's shares have been under persistent downward pressure, ...

Biotechnology firm Ocugen is facing intense selling pressure, with its stock price declining sharply in recent sessions. On Monday, the ...

The competitive landscape for treating Stargardt disease has intensified following a significant clinical announcement. While Ocugen continues developing its novel ...

All attention is focused on Ocugen as the biotechnology firm approaches a potentially defining moment. The coming week could set ...